Latest / "Isn't That Interesting?!": Breast Cancer Survivor Stories + Remarkable Research / Season 3 / Episode 1: Dr. Julie Gralow
Transcript
- 0:00From Greensboro to Seattle to ugandaearlier.org's work has
- 0:04spanned the globe in pursuit of earlier breast cancer detection.
- 0:08In today's episode of Isn't That Interesting, we speak with the
- 0:12chief medical officer of the American Society of Clinical
- 0:15Oncology about how liquid biopsies could transform the way
- 0:20cancer is detected, staged and treated.
- 0:24Joining us is Martha Kaley, founder and executive
- 0:27directorofearlier.org. This.
- 0:31Is Doctor Julie Graylow. And I am so excited to have her
- 0:36and honored to have her be able to talk with us.
- 0:39And she said been so generous with her time.
- 0:42You will find her so impressive. She's the chief medical officer
- 0:47and executive vice president of the American Society of Clinical
- 0:51Oncology. In her role as the executive
- 0:55role, she got helps guide ASC OS, global clinical strategy,
- 0:59research initiatives, quality of care programs, HealthEquity
- 1:04efforts, and cancer policy advocacy.
- 1:07In her spare time. You can only imagine what that
- 1:10is. I mean, she may get a chance to
- 1:12sleep, I don't know, but she's just very, very productive.
- 1:17And I know her brain just never stops.
- 1:20So I would like for her to have a chance to speak with you about
- 1:26where the research is going. Doctor Graylow, I know you have
- 1:30been so instrumental in so much, so many developments and I
- 1:34really appreciate that. And, and as you discussed this,
- 1:38I'd like for you to talk about the biomarkers and the
- 1:42interesting that developments for research in for earlier
- 1:47detection of breast cancer. I just in my work I have seen
- 1:52over the 30 years that I've been doing this is I think it has
- 1:57exploded in information. So I'm just going to give you
- 2:02the opportunity. This is your platform to help
- 2:05our our general public to understand the importance of all
- 2:09of this. So go ahead and say whatever
- 2:11you'd like to say. Today.
- 2:12Great. Well, thank you, Martha and I I
- 2:15want to start by really thankingearlier.org for funding
- 2:19some of our research looking at earlier detection of cancer in
- 2:24Uganda, a very interesting project.
- 2:27You talked about my current role as the Chief Medical Officer at
- 2:30ASCO, the American Society of Clinical Oncology.
- 2:34But before that, I spent 30 years as a breast medical
- 2:38oncologist, A clinical trialist, and a professor of global health
- 2:42at the University of Washington and the Fred Hutchinson Cancer
- 2:46Research Center. And then I joined ASCO shortly
- 2:50after you awarded this grant. So my, my job switched and it
- 2:55was the middle of the pandemic. But let's talk just a little bit
- 2:59about what the, the grant was and where the project is.
- 3:04The, the I said I was a professor of global health as
- 3:10well as oncology, and that was not something I started out to
- 3:14do early in my career. I kind of fell into it by being
- 3:17offered projects and the Fred Hutchinson Cancer Research
- 3:21Center established a relationship with the Uganda
- 3:24Cancer Institute decades ago now and it was based on for the most
- 3:31part HIV associated cancers and that's where the funding was.
- 3:36And while breast cancer is not an HIV associated cancer or a
- 3:42virally mediated cancer, they were seeing a lot of breast
- 3:45cancer. So they said we need a breast
- 3:48cancer consultant to be part of our efforts over there.
- 3:53And I was invited in by the Uganda Cancer Institute to to
- 3:57work with them as we developed a fellowship training program,
- 4:02established multidisciplinary tumor boards.
- 4:05For the first time, we had a a reciprocal exchange where we
- 4:09brought some of their students and faculty to Seattle and we
- 4:13went and visited there and it was really mutually beneficial.
- 4:18So this specific project in partnership with my colleague at
- 4:22the Fred Hutch, doctor Manoj Manan, who took over once I took
- 4:26on the ASCO role, and then my colleague in Uganda, Dr. Nixon
- 4:31Niazima. We said what can we do that
- 4:35would be cost effective, easy, less toxic, feasible to help
- 4:42with both detection of breast cancer and monitoring of breast
- 4:47cancer. Because the way we do things in
- 4:50the US and other high income countries is time intensive and
- 4:54resource intensive and expensive.
- 4:57So the idea was to test what we call liquid biopsies.
- 5:01And that just means we look for things in the blood, that's the
- 5:05liquid. And so this was a project
- 5:08looking at can we detect breast cancer in the blood?
- 5:15Can we reliably determine with a lot of without a lot of
- 5:20expensive imaging the the degree of spread of the cancer?
- 5:27So can we pick up metastatic spread and how reliable is it?
- 5:32And so our controls were patients who were coming in for
- 5:36breast screening, but they didn't have breast cancer.
- 5:39So we wanted to make sure we weren't picking up, you know,
- 5:43things in a normal population. And then those who we were
- 5:47testing were those who had been diagnosed with breast cancer.
- 5:51And unfortunately, I told you we had the award in 2021.
- 5:57So we had a pandemic going on and it got stalled in in getting
- 6:02started. And because it took a lot longer
- 6:05to get the COVID vaccines in Uganda, that was stalled even
- 6:10longer than you would have thought in the United States.
- 6:13But all kind of, you know, unnecessary clinical trials that
- 6:18weren't necessarily benefiting the patients were put on hold
- 6:22for several years. But it's back up and going.
- 6:26And while we originally had a small number, we were fortunate
- 6:30to also get to, to augment this project some Komen from funding
- 6:35so nice to work in in parallel so that we could do a bigger
- 6:39project. And I, I just got an update.
- 6:42We're not ready to really give numbers, but it looks very
- 6:47promising is what I can say. And we partnered, You know,
- 6:51here's another interesting thing.
- 6:53And we've done this in the US and as part of the grant, we
- 6:59said we're going to partner with the patient advocacy group, the
- 7:02EUACASA, the Uganda Women's Cancer Support Organization, who
- 7:07I had met years ago when I was there.
- 7:09And, and I, and they would help talk to patients about enrolling
- 7:14in the trials and the need for research and evidence.
- 7:18If someone was diagnosed with breast cancer, they were there
- 7:22to say, hey, I had breast cancer too.
- 7:25You know, I'm still here. Let me talk with you about it.
- 7:27Or they would help with transportation or they would
- 7:30help. How do I explain this to my
- 7:32family? So that was a very interesting
- 7:35companion to this project and and very, very important because
- 7:39you know, there is a fear of cancer of research.
- 7:44There are a lot of myths and misconceptions.
- 7:46It's not unique to Uganda, but by partnering with the patient
- 7:50advocates who strongly supported the need for evidence and for
- 7:56easier practical ways of diagnosing and monitoring breast
- 8:01cancer I I think we've been able to recruit a lot more patients
- 8:05than we would have otherwise. So, well, I just appreciate so
- 8:11much all the developments that you've you've worked on and all
- 8:15the different areas. And one that I would like for
- 8:18you to address if you can is with the circulating tumor DNA
- 8:23and the ORF 1P the protein that that you are kind of pulling
- 8:31together the information. So I think that this is I feel
- 8:35like that this is a real opportunity for breakthrough by
- 8:39by determining that. So would you address that part?
- 8:42Please. Yeah.
- 8:44So what we're looking at in the blood is circulating tumor DNA.
- 8:50So this is pieces of cancer cells that have kind of broke
- 8:57apart either because they're growing too fast or whatever,
- 9:00and they're circulating in the blood.
- 9:02And we submitted this grant about five years ago.
- 9:06So we had ideas about what might be important.
- 9:09It turns out over time we're learning more and more different
- 9:12genes are important and that's important to keep up with the
- 9:16research and switch. So there's some key genes even
- 9:20in that five year period. We now have some new drugs
- 9:25approved that are based on some of these genes and some of these
- 9:29changes in breast cancer that are really making a difference.
- 9:33And frankly, so one of the things that I'm really keeping
- 9:37an eye on is there is likely to be a new drug approved in breast
- 9:44cancer this year based on a trial where in metastatic breast
- 9:50cancer patients started their treatment for estrogen receptor
- 9:54positive. Her two negative breast cancer.
- 9:56They started a standard treatment, but they were
- 9:59monitored with blood tests over time and many of them developed
- 10:06this mutation in the estrogen receptor gene, and we call it
- 10:10ESR one over time and that was the tumor would be responding.
- 10:15But then tumors they're they're volatile.
- 10:19They're always changing their DNA.
- 10:20Sometimes that means they die. Sometimes it means they can
- 10:23survive better and that they're not going to be responsive to
- 10:26the therapy anymore. That's how tumors can slip
- 10:29through. They just have lots of
- 10:30mutations, some of which work, a lot of which don't.
- 10:34So this mutation in the estrogen receptor gene means that down
- 10:39the line, we're going to see the tumor progressing again.
- 10:42But we don't see it yet. We can't find it on scans.
- 10:46We can't find it in other ways, but we see this predictor of
- 10:50emerging resistance. And so in this trial, half of
- 10:54the women had the blood tests and were switched as soon as
- 10:58they saw this mutation. The other half we, we weren't
- 11:02monitoring, we were just doing standard of care.
- 11:04They would switch therapy at a point at which by standard
- 11:07measures that the tumor was progressing and patients did
- 11:11better with this early switch to a different therapy.
- 11:15And the FDA, their advisory committee is going to review it
- 11:19at the end of April, so this coming month.
- 11:22And we're thinking we might have the first drug approved based on
- 11:26monitoring liquid biopsies essentially and looking for
- 11:29emerging resistance. So kind of kind of a variation
- 11:33on what we set out to study and a different gene than the
- 11:37primary one that we set out to study.
- 11:40But this availability of monitoring cancers, not just
- 11:45detecting them, but monitoring over time and looking at the
- 11:49changes that are going on and the ability to change is
- 11:54fascinating to me. And it it's really showing
- 11:57precision oncology that's tailored not just to the cancer,
- 12:02but to the individual patient and what's going on.
- 12:05That is so interesting. It's it's like, you know, people
- 12:09who are have been treated for breast cancer and then and then
- 12:13it it comes back, but it's really been in the process when
- 12:18it when the gene changed. And so being able to identify
- 12:23that point and and to intercept it is just dramatic, right?
- 12:28You know, I, I think that this is just so awesome.
- 12:32Well, I find that I was reading about the phosphoproteins and,
- 12:37and the DNA methylation and the changing the particular action
- 12:43of some of the proteins. Can can you address that or how
- 12:48it like changes the sequencing for that?
- 12:51So in, in broad terms, there are lots of things that cancers do
- 12:58that are different from normal cells.
- 12:59Remember a cancer cell started from a normal cell and then, you
- 13:04know, it went haywire in some way.
- 13:07And those changes can be either the DNA level, that's the
- 13:12building block right at the DNA level.
- 13:14And it can be mutations, alterations it, but then DNA
- 13:20makes ultimately proteins and proteins are are kind of the
- 13:25actors, right? So the DNA stays in the nucleus
- 13:28of a cell, but it makes all the proteins that we use in our
- 13:32body. It makes hormones and it makes,
- 13:35you know, antibodies to fight infection.
- 13:37Those are all the proteins that are encoded in the DNA.
- 13:41Now, what cancer cells can do, they're not just mistakes in the
- 13:43DNA or changes in the DNA. There can be changes in the
- 13:47proteins. And that gets to the
- 13:48phosphorylation. A lot of proteins have phosphate
- 13:52on them and and sometimes all it can take is just a little change
- 13:57in the way the cell puts these phosphates on.
- 14:02And now the protein is acting differently, sometimes more
- 14:05potent, sometimes it's ineffective.
- 14:08And we can look at these kind of cancer specific changes in
- 14:13what's happening in these proteins over time.
- 14:16It's complicated. It's not, you know, everyday
- 14:20standard practice to do this, but we know that we can also
- 14:23monitor that too. And so looking at the DNA,
- 14:28looking at the proteins and RNA is that link in between, you
- 14:32know, so, so RNA goes to the DNA and it encodes a pattern and
- 14:36then it spits out in the end using the cell mechanisms of
- 14:40protein. So DNARNA proteins can all be
- 14:44impacted in cancer and there are lots of changes that cancer
- 14:48cells can do to survive and spread and trick the body.
- 14:53And the body in many ways still thinks itself.
- 14:57And we, our body is programmed not to attack self, right?
- 15:01But it hides itself in some ways.
- 15:04And that's what the whole, you know, immunotherapy, which is a
- 15:07very hot topic now, is all set to unmask the cancer but still
- 15:12mask all of our normal self so that we don't attack our normal.
- 15:16Body. So do you think that the perhaps
- 15:20these are the most promising assets that we can have and that
- 15:25it would maybe change the standard protocol with what what
- 15:31we're doing standard? Treatment.
- 15:33So are they? The most promising, I'd say
- 15:36they're among the most promising.
- 15:38There's a lot going on. And at the American Society of
- 15:42Clinical Oncology, we hold a big meeting at the end of May, early
- 15:46June every year. We just had a look at the 78000,
- 15:52maybe even 9000 abstracts that were submitted and we're
- 15:55planning our program. That's a lot of excitement
- 15:58that'll be in our meeting and we'll have about 4045 thousand
- 16:02people with us in Chicago to see those.
- 16:04So there's a lot of excitement. But liquid biopsies, I think
- 16:08have the potential in a few areas.
- 16:10The 1st is the very early detection and there's been a lot
- 16:17out there in the news about what we call these multi cancer early
- 16:21detection tests. And we will be talking about one
- 16:26of them. It it's looking at a blood test
- 16:29to see in a healthy population can we pick up cancer.
- 16:33And this one big test using an assay called Gallery by Grail.
- 16:40It, it was technically it was a big study done in the UK of
- 16:44healthy people that weren't at high risk for cancer.
- 16:47And it, it, the early results are it didn't meet its endpoint
- 16:51of downstaging the number of stage 3 and 4 cancers, A
- 16:55diagnosis into earlier stage cancers.
- 16:57That was what its primary endpoint was, but it did pick up
- 17:01some cancers earlier. I think we're going to see the
- 17:06real data in detail. We just know from press releases
- 17:09what it shows. And I haven't unveiled anything
- 17:11that wasn't in the press release, but I think my early
- 17:16comments about this early detection are mammography has
- 17:22been proven to save lives, cervical cancer screening
- 17:25through Pap smears, HPV tests have been proven to save lives,
- 17:29Colon cancer screening and lung cancer screening have been
- 17:33proven to save lives. These are cancers where we have
- 17:36other ways of early detection in some cases even before it
- 17:40becomes a cancer and you're not going to see the precancer in
- 17:44the blood. So I don't think liquid biopsies
- 17:48are going to replace screening at this point in time for those
- 17:51kind of cancers. But for cancer like ovarian
- 17:54cancer and pancreatic cancer, maybe kidney cancer, liver
- 17:59cancer, cancers that we don't have good screening tests for, I
- 18:03think that's where their strength is going to be.
- 18:06And those are common cancers too.
- 18:08So the early detection and screening, I do think there's a
- 18:11lot of promise for these liquid biopsies.
- 18:14And then there's the monitoring response to treatment.
- 18:18The FDA has actually accepted that something called minimal
- 18:23residual disease disease as detected by a liquid biopsy
- 18:26could be an endpoint to get a drug approved in multiple
- 18:29myeloma. And so response not measured by
- 18:34X-rays or not measured by counting the number of tumor
- 18:37cells, but by looking at what is in the blood and if the tumor
- 18:41has gone away in the blood, that would be a response.
- 18:45And that could be a way of proving a drug works and getting
- 18:49a drug approved. And then I already gave the
- 18:51example of the monitoring of what's going on real time and
- 18:55the development of resistance. I think that's fascinating and
- 18:59has tons and tons of progress. And the other benefit of
- 19:03monitoring the blood instead of just sticking the needle and if
- 19:07you have a liver metastasis or a bone metastasis is what's in the
- 19:12blood, is the cancer everywhere? It is.
- 19:15And if you just stick a needle in a spot in the liver that that
- 19:21that metastasis might have developed differently than the
- 19:25one that's in the bones and might actually have different
- 19:28changes that have gone on. So those are lots of areas where
- 19:33I think liquid biopsy has lots of promise and we've got data
- 19:38emerging in all of them and lots of research going on.
- 19:41And in part thanks to earlier.org, we can do our study
- 19:45as well well. I, I really appreciate your time
- 19:49and I, as I mentioned to you before we came on that I think I
- 19:53would love to at a later date maybe discuss further things,
- 19:58particularly after your big meeting that would be exciting.
- 20:02When does that have to be? It.
- 20:04Starts at the very end of May and overflows into the first
- 20:08couple days of June. I don't remember the exact dates
- 20:12that's. Fine, we, I will make it a point
- 20:15to send you contact about that and maybe we can discuss that at
- 20:20that later date. So I really appreciate your
- 20:22spending so much time with us and it was you're so generous to
- 20:27do that and helping us all understand why research is it's
- 20:33not a word that has to you have to be afraid of that.
- 20:36It is something that's just is is with us now and we can do
- 20:41this. So thank you so much, Doctor.
- 20:44OK, thank you. So.
- 20:45Much, Martha. OK, bye, bye.
- 20:47Thanks. Bye.
- 20:48Bye. Bye.
- 20:49Bye bye this episode. Of isn't that Interesting was
- 20:52made possible thanks to volunteers and donors just like
- 20:55you. It was hosted by Martha Kaley,
- 20:57founderofearlier.org and edited by Liam Mcburney.
- 21:01I'm Valerie Amsterdam, reminding you that for the last 30 years,
- 21:05this is North Carolina based organization has helped fund
- 21:08groundbreaking research all over the world from molecular imaging
- 21:13to a sensitive blood test for breast cancer.
- 21:16Plain and simple, earlier detection saves lives.
- 21:19And you can help host a fundraising event, make a
- 21:21donation for volunteer your time.
- 21:24You can find us not only on the web, but on Facebook and
- 21:27Instagram too. Let's change the picture of
- 21:30breast cancer together.